Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
Identifieur interne : 001721 ( Main/Exploration ); précédent : 001720; suivant : 001722Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
Auteurs : Hongying Mo ; Guangqiao Zeng ; Xiaolan Ren ; Hui Li ; Changwen Ke ; Yaxia Tan ; Chaoda Cai ; Kefang Lai ; Rongchang Chen ; Moira Chan-Yeung [Canada] ; Nanshan ZhongSource :
- Respirology [ 1323-7799 ] ; 2006-01.
English descriptors
- Teeft :
- Antibodies titres, Antibody, Antibody neutralization test, Antibody response, Antibody titres, Assay, Blood samples, British columbia, Convalescent, Convalescent patients, Convalescent sera, Coronavirus, Elisa, Guangdong province, Guangzhou, Guangzhou institute, Indirect assay, Neutralization, Neutralization test, Neutralizing, Neutralizing antibodies, Novel coronavirus, Respiratory disease, Respiratory diseases, Respiratory syndrome, Rinsing buffer, Sars, Sars coronavirus, Sars patients, Serial sera, Serum antibodies, Serum samples, Similar results, Syndrome, Titre, Vero cells, Virus neutralization test, World health organization.
Abstract
Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.
Url:
DOI: 10.1111/j.1440-1843.2006.00783.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000520
- to stream Istex, to step Curation: 000487
- to stream Istex, to step Checkpoint: 000230
- to stream Main, to step Merge: 001727
- to stream Main, to step Curation: 001721
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><author><name sortKey="Mo, Hongying" sort="Mo, Hongying" uniqKey="Mo H" first="Hongying" last="Mo">Hongying Mo</name></author><author><name sortKey="Zeng, Guangqiao" sort="Zeng, Guangqiao" uniqKey="Zeng G" first="Guangqiao" last="Zeng">Guangqiao Zeng</name></author><author><name sortKey="Ren, Xiaolan" sort="Ren, Xiaolan" uniqKey="Ren X" first="Xiaolan" last="Ren">Xiaolan Ren</name></author><author><name sortKey="Li, Hui" sort="Li, Hui" uniqKey="Li H" first="Hui" last="Li">Hui Li</name></author><author><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name></author><author><name sortKey="Tan, Yaxia" sort="Tan, Yaxia" uniqKey="Tan Y" first="Yaxia" last="Tan">Yaxia Tan</name></author><author><name sortKey="Cai, Chaoda" sort="Cai, Chaoda" uniqKey="Cai C" first="Chaoda" last="Cai">Chaoda Cai</name></author><author><name sortKey="Lai, Kefang" sort="Lai, Kefang" uniqKey="Lai K" first="Kefang" last="Lai">Kefang Lai</name></author><author><name sortKey="Chen, Rongchang" sort="Chen, Rongchang" uniqKey="Chen R" first="Rongchang" last="Chen">Rongchang Chen</name></author><author><name sortKey="Chan Eung, Moira" sort="Chan Eung, Moira" uniqKey="Chan Eung M" first="Moira" last="Chan-Yeung">Moira Chan-Yeung</name></author><author><name sortKey="Zhong, Nanshan" sort="Zhong, Nanshan" uniqKey="Zhong N" first="Nanshan" last="Zhong">Nanshan Zhong</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:15DD49E0ED3C4B260E52012856E849161EB2D3A8</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1440-1843.2006.00783.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000520</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000520</idno><idno type="wicri:Area/Istex/Curation">000487</idno><idno type="wicri:Area/Istex/Checkpoint">000230</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000230</idno><idno type="wicri:doubleKey">1323-7799:2006:Mo H:longitudinal:profile:of</idno><idno type="wicri:Area/Main/Merge">001727</idno><idno type="wicri:Area/Main/Curation">001721</idno><idno type="wicri:Area/Main/Exploration">001721</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><author><name sortKey="Mo, Hongying" sort="Mo, Hongying" uniqKey="Mo H" first="Hongying" last="Mo">Hongying Mo</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Zeng, Guangqiao" sort="Zeng, Guangqiao" uniqKey="Zeng G" first="Guangqiao" last="Zeng">Guangqiao Zeng</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Ren, Xiaolan" sort="Ren, Xiaolan" uniqKey="Ren X" first="Xiaolan" last="Ren">Xiaolan Ren</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Li, Hui" sort="Li, Hui" uniqKey="Li H" first="Hui" last="Li">Hui Li</name><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Tan, Yaxia" sort="Tan, Yaxia" uniqKey="Tan Y" first="Yaxia" last="Tan">Yaxia Tan</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Cai, Chaoda" sort="Cai, Chaoda" uniqKey="Cai C" first="Chaoda" last="Cai">Chaoda Cai</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Lai, Kefang" sort="Lai, Kefang" uniqKey="Lai K" first="Kefang" last="Lai">Kefang Lai</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Chen, Rongchang" sort="Chen, Rongchang" uniqKey="Chen R" first="Rongchang" last="Chen">Rongchang Chen</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Chan Eung, Moira" sort="Chan Eung, Moira" uniqKey="Chan Eung M" first="Moira" last="Chan-Yeung">Moira Chan-Yeung</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Zhong, Nanshan" sort="Zhong, Nanshan" uniqKey="Zhong N" first="Nanshan" last="Zhong">Nanshan Zhong</name><affiliation></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: nanshan@vip.163.com</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Respirology</title><title level="j" type="alt">RESPIROLOGY</title><idno type="ISSN">1323-7799</idno><idno type="eISSN">1440-1843</idno><imprint><biblScope unit="vol">11</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="49">49</biblScope><biblScope unit="page" to="53">53</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-01">2006-01</date></imprint><idno type="ISSN">1323-7799</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1323-7799</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antibodies titres</term><term>Antibody</term><term>Antibody neutralization test</term><term>Antibody response</term><term>Antibody titres</term><term>Assay</term><term>Blood samples</term><term>British columbia</term><term>Convalescent</term><term>Convalescent patients</term><term>Convalescent sera</term><term>Coronavirus</term><term>Elisa</term><term>Guangdong province</term><term>Guangzhou</term><term>Guangzhou institute</term><term>Indirect assay</term><term>Neutralization</term><term>Neutralization test</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Novel coronavirus</term><term>Respiratory disease</term><term>Respiratory diseases</term><term>Respiratory syndrome</term><term>Rinsing buffer</term><term>Sars</term><term>Sars coronavirus</term><term>Sars patients</term><term>Serial sera</term><term>Serum antibodies</term><term>Serum samples</term><term>Similar results</term><term>Syndrome</term><term>Titre</term><term>Vero cells</term><term>Virus neutralization test</term><term>World health organization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Cai, Chaoda" sort="Cai, Chaoda" uniqKey="Cai C" first="Chaoda" last="Cai">Chaoda Cai</name><name sortKey="Chen, Rongchang" sort="Chen, Rongchang" uniqKey="Chen R" first="Rongchang" last="Chen">Rongchang Chen</name><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name><name sortKey="Lai, Kefang" sort="Lai, Kefang" uniqKey="Lai K" first="Kefang" last="Lai">Kefang Lai</name><name sortKey="Li, Hui" sort="Li, Hui" uniqKey="Li H" first="Hui" last="Li">Hui Li</name><name sortKey="Mo, Hongying" sort="Mo, Hongying" uniqKey="Mo H" first="Hongying" last="Mo">Hongying Mo</name><name sortKey="Ren, Xiaolan" sort="Ren, Xiaolan" uniqKey="Ren X" first="Xiaolan" last="Ren">Xiaolan Ren</name><name sortKey="Tan, Yaxia" sort="Tan, Yaxia" uniqKey="Tan Y" first="Yaxia" last="Tan">Yaxia Tan</name><name sortKey="Zeng, Guangqiao" sort="Zeng, Guangqiao" uniqKey="Zeng G" first="Guangqiao" last="Zeng">Guangqiao Zeng</name><name sortKey="Zhong, Nanshan" sort="Zhong, Nanshan" uniqKey="Zhong N" first="Nanshan" last="Zhong">Nanshan Zhong</name></noCountry><country name="Canada"><noRegion><name sortKey="Chan Eung, Moira" sort="Chan Eung, Moira" uniqKey="Chan Eung M" first="Moira" last="Chan-Yeung">Moira Chan-Yeung</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001721 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001721 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:15DD49E0ED3C4B260E52012856E849161EB2D3A8
|texte= Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
}}
| This area was generated with Dilib version V0.6.33. |  |